Remoxy meets Phase III endpoint for pain

Pain Therapeutics and King Pharmaceuticals have announced positive results of a Phase III study of Remoxy for patients with chronic participated pain. Remoxy is an abuse-deterrent version of long-acting oxycodone. Remoxy has the benefits of oxycodone but can be prescribed by doctors who want to minimize the risks of abuse, misuse or diversion. With prescription pain drug use on the rise, preventing abuse is a major concern. Pain Therapeutics expects to file an NDA for Remoxy in the second half of 2008. If approved, Remoxy will be the first oxycodone on the market designed to deter abuse.

- see this release for more

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Canadian biotech AbCellera has nabbed a meaty $105 million series B funding round as it looks to boost its antibody work and seek out new potential me